RGN-259 early results
RegeneRx has an orphan Phase 3 clinical trial of its drug RGN-259 for neurotrophic keratopathy ongoing. Some early information about results was released by its joint venture partner, so they put out a press release to clarify.
The report said that 7 of 17 patients had healed completely from a non-healing corneal wound. Since the trial is ongoing, it's not known whether those 7 were on the drug or placebo. Always nice to get news of any kind about these trials though!